PHARMACEUTICALS
SECTOR HIGHLIGHTS

CURRENT SCENARIO

- **Market size:** USD 36 Bn
- **FDI Inflows:** USD 16.2 Bn (April 2000 – September 2019)
- **Market Growth Rate:** 7-8%
- **Pharma Exports:** USD 18.3 Bn
- **Over 60,000** generic brands across 60 therapeutic categories

India’s Ranking:

- **Exports:** 20% of global generics by volume, making it the largest provider of generic medicines globally
- **Major Segments:** Generic Drugs, OTC Medicines and Patented Drugs
- **Indian pharmaceuticals are exported to multiple countries**
- **Indian Pharmaceuticals market:** 3rd in terms of volume (10% of the global industry) and 14th in terms of value
- **Department of Pharmaceuticals announced plans to establish Pharma parks & clusters in various States**
- **Leader in global supply of DPT, BCG and Measles vaccines**

FUTURE POTENTIAL

- **Indian pharmaceutical market is expected to reach USD 100 Bn by 2025**
- **Focus States:** Gujarat, Telangana, Andhra Pradesh, Karnataka, and Himachal Pradesh
A. Demand-side Factors

Accessibility

• Over **USD 200 Bn**
  to be spent on medical infrastructure in the next decade

• Over **160,000**
  hospital beds expected to be added each year in the next decade

Affordability

• **Rising income**
  ~73Mn households expected to shift to the middle class with over the next 10 yrs

• **Ayushman Bharat**
  The National Health Protection Scheme is the largest government funded healthcare program in the world, which is expected to benefit ~100 Mn poor and vulnerable families in the country by providing a cover of up to INR 5 lakh (~USD 6900) per family per year for secondary and tertiary care.

• **Availability of affordable medicines under the**
  **Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)**
  has led to 50-90% savings for Indian citizens and made generic medicines easily available through the PMBJP Kendras across the country

B. Supply-side Factors

Epidemiological Factors

• Patient pool expected to increase over **20%**
  in the next 10 years, given population growth and lifestyle changes

• New diseases & lifestyle changes to boost demand for drugs and devices

Medical Tourism

• Medical tourism industry expected to grow to **USD 13.3 Bn**
  by 2022

Patented Drugs

• Following the introduction of product patents, several multinational companies are expected to launch patented drugs in India

• Patents for branded molecules with cumulative global sales of over **USD 251 Bn**
  are expected to expire between 2018 and 2024, giving opportunities to Indian pharmaceuticals

Medical Infrastructure

• Pharma companies have increased spending to tap rural markets and several state governments have launched medical device and pharma parks

Medical Infrastructure
B. Supply-side Factors

Cost Efficiency

- India’s cost of production is nearly **33%** lower than that of the US with labour costs 50–55% lower than western countries

Talent Pool

- India is the **2nd largest** provider of pharma and biotech professionals in the world, after China. Other leading countries include USA & Brazil
POLICY SUPPORT & INCENTIVES

1. FDI Policy
   - 100% under automatic route for greenfield projects
   - 100% under government route for brownfield investments
   - 74% under automatic route for brownfield investments

2. Skill Development
   - Transformation of National Institutes of Pharmaceutical Education & Research (NIPERS) to Innovation Hubs focused on becoming centers of excellence for advanced research in pharmaceutical studies
   - Currently 7 NIPERs are functioning in the states of Ahmedabad, Guwahati, Hajipur, Hyderabad, Kolkata, Mohali and Raebareli

   - The policy is entirely compliant with the WTO’s agreement on TRIPS

   - Making quality medicines available at affordable prices through exclusive outlets “Pradhan Mantri Bhartiya Janaushadhi Kendras”
   - Product basket covers more than 800 medicines and 154 surgicals & consumables

5. Similar Biologics Guidelines (2016)
   - Regulatory pathway regarding manufacturing process and safety, efficacy and quality aspects for similar Biologics
   - Pre-market regulatory requirements including comparability exercise for quality, preclinical and clinical studies and post market regulatory requirements

   - Aimed at attainment of highest possible level of health and well-being for all through a preventive and promotive health care orientation in developmental policies, and universal access to good quality health care services
   - Increasing access, improving quality and lowering the cost of healthcare delivery
SECTOR OPPORTUNITIES

01 Active Pharmaceutical Ingredients/ Bulk Drugs
- 500+ APIs manufactured in India and exported to other countries

02 Generics
- Generic drugs account for 20% of global exports in terms of volume, making India the largest provider of generic medicines globally
- India’s cost of production is nearly 33% lower than that of the US with labour costs 50–55% cheaper than in Western countries
- India’s generics drug market accounts for around 70% of the India pharmaceutical industry and it is expected to reach USD 27.9 Bn by 2020

03 Vaccines
India currently exports vaccines to about 150 countries. 80% of the global ARVs to combat AIDS are supplied by Indian firms

04 Contract Manufacturing and Research
India has a sustainable competitive advantage due to a large, technically knowledgeable workforce, WHO-GMP approved production premises and a substantially (40%) lower cost of operation and production. There are 1000+ players in this sector in India

05 Biosimilars
There are 70+ approved biosimilar products in India and the domestic market is expected to reach USD 2.2 Bn by 2025. Multiple biologic drugs are expected to go off patent—creating an opportunity for biosimilar products
**KEY STAKEHOLDERS**

- Department of Pharmaceuticals (DoP)
- Central Durg Standards Control Organization (CDSCO)
- National Pharmaceutical Pricing Authority (NPPA)
- Organisation Of Pharmaceutical Producers of India (OPPI)
- Indian Pharmaceutical Alliance (IPA)

**INDUSTRY CLUSTERS/ZONES**

**PHARMACEUTICAL CLUSTERS**

- Captive R&D Units
- Contract R&D Units
- Established Bulk Drug Cluster
- Established Formulation Cluster
- Emerging Bulk Drug Cluster
- Emerging Formulation Cluster

Map not to scale
KEY PLAYERS IN INDIA

- Sun Pharmaceuticals Industries Ltd
- Lupin Ltd
- Aurobindo Pharma Ltd
- Cipla Ltd
- Dr Reddy’s Laboratories
- Mylan NV
- Glenmark Pharmaceuticals Ltd
- GlaxoSmithKline Pharmaceuticals Ltd
- TEVA Pharmaceuticals Industries Ltd
- MSD
- Sanofi

All information in this brochure was last updated on May 06th, 2020.
HOW WE HELP INVESTORS

- RESEARCH CONTENT PROVIDED
- POLICY ADVISORY/REPRESENTATION
- STAKEHOLDER MEETING
- SITE VISITS
- LOCATION ANALYSIS
- ISSUE RESOLUTION
- REGULATORY CLEARANCE FACILITATION

To find out more
https://www.investindia.gov.in/sector/pharmaceuticals

Phone No: 011 2304 8101
Email ID: pharma@investindia.org.in

First Floor,
Vigyan Bhawan Annexe,
Maulana Azad Road, New Delhi - 110011

To know more
@investindia @invest-india @investindiaofficial
Scan QR Code